Objective Objectives of the proposal: Heart Failure (HF) is estimated to cost the EU economy €196 billion a year. Currently, patients are treated with the highest pharmaceutical doses of antiRAS agents, which cause severe side effects and reduce the patients’ quality of life. Moreover, treatment responses are highly variable. This study aims to enable imaging-guided treatment optimization by using a radiolabelled novel angiotensin 1 receptor (AT1) blocker analogue in a small animal model of myocardial infarction (MI). Positron emission tomography (PET) as a cutting-edge method of evaluating HF pathophysiology at a molecular level will be employed to optimize treatment.How the objectives will be achieved: MI will be obtained by ligation of the coronary artery in Wistar rats. Subsequently, PET imaging with a dedicated small animal system (mciroPET) will be performed. A multiple set of cardioneuronal PET tracers provided by the partner institution at Johns Hopkins University will be used to measure the extent of global and regional neurohumoral abnormalities in rat hearts following different degrees of ischemic insult. The relationship between neurohumoral system alterations and subsequent left ventricular remodelling will be determined by microPET and Magnetic Resonance Imaging to assess deterioration of ventricular geometric parameters. Using the novel AT1-ligand, imaging-guided dose-derived therapeutic concepts for Wistar rats will be established in vivo with the aim to transfer this technique to the clinic in a long term perspective. Relevance to the Work Programme: I envisage that in the future a single cardiac PET scan prior to treatment initiation will be sufficient to estimate the appropriate drug dose in any given HF patient. This new concept of individualized drug dose determination has the potential to lead to personalized treatment for one of the most frequent fatal and expensive diseases and thereby contributes to the reduction of the economic burden of the EU. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicineradiologynuclear medicinemedical and health sciencesbasic medicineimmunologyengineering and technologymedical engineeringdiagnostic imagingmagnetic resonance imagingmedical and health sciencesclinical medicinecardiology Keywords Heart Failure Heart Rat Sympathetic Nerve Imaging Personalized Treatment Radionuclide Positron emission tomography PET Myocardial Infarction Ischemia Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2015-GF - Marie Skłodowska-Curie Individual Fellowships (IF-GF) Call for proposal H2020-MSCA-IF-2015 See other projects for this call Funding Scheme MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF) Coordinator UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT Net EU contribution € 239 860,80 Address Josef-schneider-strasse 2 97080 Wurzburg Germany See on map Region Bayern Unterfranken Würzburg, Kreisfreie Stadt Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 Partners (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all Partner Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement. JOHNS HOPKINS UNIVERSITY United States Net EU contribution € 0,00 Address North charles street 3400 21218 Baltimore See on map Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 160 130,40
